Skip to product information
1 of 1

GeneBio Systems

c-Abl (phospho-Tyr89) rabbit pAb

c-Abl (phospho-Tyr89) rabbit pAb

SKU:ES17895

Regular price $477.40 CAD
Regular price Sale price $477.40 CAD
Sale Sold out
Shipping calculated at checkout.

Size: 100μL

Source:Rabbit

Applications:WB

Reactivity:Human;Rat;Mouse;

Dilution:WB 1:1000-2000

Immunogen:Synthesized phosho peptide around human c-Abl (Tyr89)

Storage_stability:-20°C/1 year

Clonality:Polyclonal

Isotype:IgG

Concentration:1 mg/ml

Observed_band(KD):140(200kd BCR-ABL complex)

Human_gene_id:25

Human_swiss_prot_no:P00519

Subcellular_location:Cytoplasm, cytoskeleton. Nucleus. Mitochondrion . Shuttles between the nucleus and cytoplasm depending on environmental signals. Sequestered into the cytoplasm through interaction with 14-3-3 proteins. Localizes to mitochondria in response to oxidative stress (By similarity). .; [Isoform IB]: Nucleus membrane; Lipid-anchor. The myristoylated c-ABL protein is reported to be nuclear.

Other_name:Tyrosine-protein kinase ABL1 (EC 2.7.10.2) (Abelson murine leukemia viral oncogene homolog 1) (Abelson tyrosine-protein kinase 1) (Proto-oncogene c-Abl) (p150)

Background:This gene is a protooncogene that encodes a protein tyrosine kinase involved in a variety of cellular processes, including cell division, adhesion, differentiation, and response to stress. The activity of the protein is negatively regulated by its SH3 domain, whereby deletion of the region encoding this domain results in an oncogene. The ubiquitously expressed protein has DNA-binding activity that is regulated by CDC2-mediated phosphorylation, suggesting a cell cycle function. This gene has been found fused to a variety of translocation partner genes in various leukemias, most notably the t(9;22) translocation that results in a fusion with the 5' end of the breakpoint cluster region gene (BCR; MIM:151410). Alternative splicing of this gene results in two transcript variants, which contain alternative first exons that are spliced to the remaining common exons. [pr

View full details